Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Neurology | Family Medicine

Clinical Trials: Alzheimer's Disease


A listing of clinical trials currently looking for volunteers to enroll in Alzheimer's Disease studies. Click on the closest city to find more detailed information on a research study in your area.

Arizona

Sun City : Banner Sun Health Research Institute Updated

A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between florbetapir (18F) PET scan status and cognitive decline

Sun City : Banner Sun Health Research Institute

Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)

Sun City : Banner Sun Health Research Institute Updated

Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer ’s Disease or Mild Alzheimer's Disease

View More »

Phoenix :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Phoenix : Banner Alzheimer Institute

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Sun City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Tucson : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

California

Encino : Pharmacology Research Institute, Encino

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer's Disease

Encino : Pharmacology Research Institute, Encino

Study of an investigational medication for the treatment of Alzheimer's Disease

Fresno : The Margolin Brain Institute Updated

Research study for treatment of symptoms of agitation in patients with Alzheimer’s disease.

Glendale : California Clinical Trials Medical Group, Inc.

Alzheimer's Disease Study

Long Beach : CNS Network

A Phase I trial investigating a new therapy to treat Mild Alzheimer’s disease

Long Beach : CNS Network

A Phase II study of an investigational medication to treat Mild-to-Moderate Alzheimer's Disease

Long Beach : CNS Network

A Phase III trial investigating Bapinezumab as a treatment of Mild-to-Moderate Alzheimer's Disease in APOE-4 Non-Carriers

Long Beach : CNS Network

A Phase III trial investigating IGIV therapy on Mild-to-Moderate Alzheimer’s disease

Los Alamitos : Pharmacology Research Institute, Los Alamitos

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer's Disease

Los Alamitos : Pharmacology Research Institute, Los Alamitos

Study of an investigational medication for the treatment of Alzheimer's Disease

Newport Beach : Pharmacology Research Institute, Newport Beach

Study of an investigational medication for mild to moderate Alzheimer's Disease

Newport Beach : Pharmacology Research Institute, Newport Beach

Study of an investigational medication for the treatment of Alzheimer's Disease

Sacramento : Sutter Institute for Medical Research (SIMR)

Mild Cognitive Impairment

Santa Ana : Apex Research Institute

Alzheimers? Be a Part of Research.

Santa Rosa : Radiant Research - Santa Rosa

Alzheimer's Disease Research Study

Sherman Oaks : California Neuroscience Research Medical Group, Inc. Updated

Clinical research study of an investigational medication vs. placebo for agitation in persons with Alzheimer’s disease.

View More »

Aliso Viejo : Avanir Pharmaceuticals

PRISM Registry: Pseudobulbar Affect Registry Series

Fresno :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Fresno :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Fresno : Site Reference ID/Investigator# 66528

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Glendale : California Clinical Trials Medical Group, Inc.

Evaluation of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease

Glendale : Glendale Adventist Medical Center

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Long Beach : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Long Beach : Site Reference ID/Investigator# 69602

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

San Francisco : Site Reference ID/Investigator# 66527

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

San Francisco : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

San Francisco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

San Francisco :

VI-1121 for the Treatment Alzheimer's Disease

Sherman Oaks :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Valencia : Sanguine Biosciences

A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery

Colorado

Boulder : Alpine Clinical Research Center

New Investigational Medication for Autism, Asperger's Disorder, or Pervasive Developmental Disorder in Pediatric Patients (PDD-NOS)

Boulder : Alpine Clinical Research Center

New Investigational Medication for Mild Alzheimer's Disease

Denver : Radiant Research - Denver

Memory Loss Research Study

View More »

Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Connecticut

Waterbury : Chase Medical Research, LLC

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E4 Non-Carriers.

View More »

Hamden : Site Reference ID/Investigator# 66530

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

New Haven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Florida

Hallandale Beach : MD Clinical

Is your memory loss just a sign of age, or something else?

Miami : Miami Jewish Health Systems Updated

Alzheimer’s Research Study ITN# 12038

Miami : Pharmax Research Clinic, Inc.

Alzheimer's Disease

Ocala : Renstar Medical Research

Alzheimer's Disease

St. Petersburg : Meridien Research

Alzheimer's Disease

Tampa : Axiom Clinical Research of Florida

A clinical research study for patients with Mild Alzheimer's Disease

View More »

Brooksville : Meridien Research

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Delray Beach : Site Reference ID/Investigator# 56503

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Delray Beach : Site Reference ID/Investigator# 66522

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Delray Beach : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Delray Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Delray Beach : Site Reference ID/Investigator# 84178

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Delray Beach : Site Reference ID/Investigator# 73493

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Fort Myers :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Fort Myers : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Hallandale Beach : MD Clinical

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Hallandale Beach : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Hallendale Beach : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Miami : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Miami :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Ocala : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Orlando : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Orlando : Site Reference ID/Investigator# 66524

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Orlando : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Orlando : Compass Research, LLC

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Orlando : Compass Research

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Sunrise :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Sunrise :

VI-1121 for the Treatment Alzheimer's Disease

Tampa : Site Reference ID/Investigator# 66531

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Tampa : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

West Palm Beach : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

West Palm Beach :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

West Palm Beach : Site Reference ID/Investigator# 56514

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

West Palm Beach : Site Reference ID/Investigator# 66529

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

West Palm Beach : Site Reference ID/Investigator# 73496

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Georgia

Atlanta : NeuroTrials Research

New Alzheimer’s Disease Research

View More »

Atlanta : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Atlanta : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Savannah : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Illinois

Elk Grove Village : Alexian Brothers Hospital Network

A multinational, multicenter, randomized, double-blind, parallel-group, placebo- controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy

Elk Grove Village : Alexian Brothers Hospital Network

A phase 2 multicenter, double-blind, placebo controlled, parallel group study of PF-04447943 in subjects with mild to moderate Alzheimer's Disease on stable Donepezil therapy.

Elk Grove Village : Alexian Brothers Hospital Network

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy and Safety Trial of Bapineuzumab (AAB-001) in Subjects with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E e4 Carriers

Elk Grove Village : Alexian Brothers Hospital Network

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer’s Diseases

View More »

Elk Grove Village :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Elk Grove Village : Site Reference ID/Investigator# 62611

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Elk Grove Village : Site Reference ID/Investigator# 66526

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Kentucky

Lexington : University of Kentucky Chandler Medical Center

Can Brain Waves Diagnose Alzheimer’s Disease?

Lexington : University of Kentucky Chandler Medical Center

Down Syndrome, Aging & Alzheimer's Disease Study

Lexington : University of Kentucky Chandler Medical Center

Turning off the Alzheimer switch!

View More »

Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Louisville :

VI-1121 for the Treatment Alzheimer's Disease

Massachusetts

Boston : Beth Israel Deaconess Medical Center

Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients

Plymouth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Quincy : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Qunicy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Michigan

Kalamazoo : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Kalamazoo : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Mississippi

Hattiesburg : Hattiesburg Clinic Neurological Research Center

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers

Hattiesburg : Hattiesburg Clinic Neurological Research Center

Genentech ABE4955g for Mild to Moderate Alzheimer's disease

View More »

Flowood : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Missouri

Creve Coeur : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Creve Coeur : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

St. Louis : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

St. Louis : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

St. Louis : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Nevada

Las Vegas : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

New Jersey

Stratford : University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine

Alzheimer's disease study for mild to moderate AD.

View More »

Eatontown : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Eatontown : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Eatontown : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Edison : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Edison : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Oakhurst : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Oakhurst : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Princeton : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Toms River :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Toms River : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Toms River :

VI-1121 for the Treatment Alzheimer's Disease

New York

New Hyde Park : Parker Jewish Institute

This study will investigate the safety and efficacy of immune globulin intravenous, for the treatment of mild to moderate Alzheimer's Disease.

New York : Biomedical Research Alliance of New York

People with Alzheimer’s disease are asked to participate in a research study being conducted by North Shore-Long Island Jewish Health System.

View More »

New Windsor :

VI-1121 for the Treatment Alzheimer's Disease

Staten Island : Site Reference ID/Investigator# 56506

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Staten Island : Site Reference ID/Investigator# 66525

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

North Carolina

Greensboro : Guilford Neurologic Associates

Impact of Florbetapir F 18 PET on the Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Raleigh : Multi-Specialty Research Associates of NC

Is Alzheimer’s Disease affecting your loved one?

Raleigh : Wake Research Associates

New Clinical Research Study of Alzheimer’s Disease

Winston-Salem : PMG Research of Winston-Salem

Do you care for someone afflicted with Alzheimer's Disease?

Winston-Salem : PMG Research of Winston-Salem

MEMORIES MATTER! Is Alzheimer's Disease taking away the enjoyment in your life?

View More »

Charlotte : Call for Information (Investigational Site 0013)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Durham : Duke Health Center at Morreene Road

Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias

Durham :

VI-1121 for the Treatment Alzheimer's Disease

Raleigh :

VI-1121 for the Treatment Alzheimer's Disease

Ohio

Beechwood : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Centerville :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Toledo : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Oklahoma

Oklahoma City : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Tulsa : Call for Information (Investigational Site 0055)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Oregon

Pennsylvania

Jenkintown : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

South Carolina

Greer : Radiant Research - Greer

Clinical Research Study for Alzheimer's Disease

Tennessee

Nashville : Clinical Research Associates, Inc.

Alzheimer's Disease Research Study

Texas

Dallas : Texas Neurology, PA

Alzheimer's Research Study

Dallas : Texas Neurology, PA

Mild Cognitive Impairment

View More »

San Antonio : CEDRA Clinical Research, LLC

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

Utah

Salt Lake City : Lifetree Clinical Research

Alzheimer's Research Study

Salt Lake City : CRI Lifetree

Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer ’s Disease or Mild Alzheimer's Disease

Salt Lake City : CRI Lifetree

The objectives of the study are to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of AVP-923 compared to placebo, for the treatment of symptoms of agitation in patients with AD.

Salt Lake City : CRI Lifetree

To assess the safety, tolerability, and the effects of of BMS-241027 on CSF Tau Nterminal domain fragment in subjects with mild Alzheimer’s Disease (AD).

Salt Lake City : CRI Lifetree

To evaluate the effect of gantenerumab vs. placebo on the change in the Clinical Dementia Rating scale Sum of Boxes (CDR-SOB), a global measure of cognition and functional ability

View More »

Salt Lake City :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Vermont

Bennington : Site Reference ID/Investigator# 66523

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Burlington : Fletcher Allen Health Care-Clinical Neuroscience Research Unit

Quetiapine for the Treatment of Insomnia in Alzheimer's Disease

Australia

Randwick : GSK Investigational Site

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers

Canada

Gatineau : Site Reference ID/Investigator# 71793

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Medicine Hat :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Montreal : Site Reference ID/Investigator# 71794

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Peterborough : Site Reference ID/Investigator# 71798

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Toronto :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

View More »

Toronto : Site Reference ID/Investigator# 71795

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Verdun : Site Reference ID/Investigator# 71796

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

China

Baoding : Hebei mental health center

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Beijing : Novartis Investigative Site

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Beijing : Peking University Institute of Mental Health

Memantine on Aggression and Agitation of Alzheimer's Disease (AD)

Beijing : Beijing HuiLongGuan Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Beijing : Beijing Shijitan Hospital, EMU

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

View More »

Changchun : The first Affiliated Hospital of Jilin University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Guangzhou : Guangzhou Brain Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Guilin : Affiliated Hospital of Guilin Medical University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Hangzhou : The First Affiliated Hospital of Medical School of Zhejiang University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Kunming : First Affiliated Hospital of Kunming Medical University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Nanjing : Jiangsu Province Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai Mental Health Center

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai Tenth People's hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai Changzheng Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai First People's Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Czech Republic

Chocen : Policlinic

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Kladno : BRAIN-SOULTHERAPY s.r.o.

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Litoměřice : Bialbi.s.r.o. Psychiatrické oddělení

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Olomouc : Psychiatricka Ambulance

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Olomouc : Vojenska Nemocnice Psychiatricke oddeleni

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

View More »

Praha : Clintrial

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Praha : PRAGTIS s.r.o.

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Prerov : Psychosocialni centrum

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

France

Aix En Provence : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Bordeaux :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Caen : CHU de la Côte de Nacre

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Cahors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Castres : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

View More »

Clermont-Ferrand : CHU Clermont-Ferrand

Alzheimer and Sleep

Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Foix Cedex : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Lavaur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Léon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Lille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Limoges : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Limoges Cedex : Site Reference ID/Investigator# 77833

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Marseille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Marseille : Hôpital Sainte-Marguerite

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Montauban Cedex : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Montpellier cedex : CHU Gui de Chauliac

Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers

Nancy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Nantes : Hôpital Guillaume et René Laennec

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Nice :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Nice : Hôpital de l'Archet

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Paris :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Paris :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Paris : Pitié-Salpêtrière Hospital

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris : Pitié-Salpêtrière Hospital - Centre du Langage et de Neuropsychologie

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris : Pitié-Salpêtrière Hospital - Fédération de Neurologie

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris Cedex 10 : Site Reference ID/Investigator# 68704

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Rennes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Rennes : Hôpital Pontchaillou

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Rouen : Hôpital Charles Nicolle

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Saint-Brieuc : Centre Hospitalier

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Saint-Etienne : Hôpital Bellevue

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Strasbourg : Hôpital Civil

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Toulouse :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Toulouse :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Tours : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Tours Cedex 9 :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Vic-En-Bigorre : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Germany

Berlin :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Berlin : Site Reference ID/Investigator# 68768

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Erlangen :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Frankfurt :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Freiburg : Site Reference ID/Investigator# 68764

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

View More »

Huettenberg : Site Reference ID/Investigator# 68767

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Mittweida : Site Reference ID/Investigator# 69960

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Muenchen :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Munich : Site Reference ID/Investigator# 68765

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Siegen :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Greece

Athens : Site Reference ID/Investigator# 68732

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Athens : Site Reference ID/Investigator# 68730

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Haidari, Athens : Site Reference ID/Investigator# 68731

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Thessaloniki : Site Reference ID/Investigator# 68735

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Israel

Tel Aviv : Merchav Clinics

Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease

Tel Aviv : Tel Aviv Sourasky Medical Center, Neurology Department

Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease

Italy

Japan

Akita : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Anjo-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Atsugi : Pfizer Investigational Site

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Azumino-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Bunkyo : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

View More »

Bunkyo-ku : Pfizer Investigational Site

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Fukui-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Fukuoka-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Fukuoka-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Izunokuni : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Kamakura-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Kamakura-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kansai : Kansai region

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Kanto : Kanto region,

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Kasukabe-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kawasaki-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Kita-gun : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Kobe : Research Site

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Kochi N/A : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Koshi-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Koshi-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kumamoto : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Kyoto : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Kyoto-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Kyoto-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kyushu : Kyushu region

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Miyoshi-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Miyoshi-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Nagoya : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Ohtake : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Osaka : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Osaka-City : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Sagamihara : Pfizer Investigational Site

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Saitama N/A : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Setagaya-ku : Pfizer Investigational Site

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Suwa : Pfizer Investigational Site

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Takatsuki : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Toakai : Tokai region

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Tohoku : Tohoku region

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Tokyo : Research Site

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Tokyo : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Uji : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Urayasu N/A : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Yokohama : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Yokohama : Updated

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Korea, Republic of

Goyang : National Health Insurance Corporation Ilsan Hospital

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Incheon : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Incheon : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Seongnam-si : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Seongnam-si : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

View More »

Seoul : SKChemicals invetigational site

A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease

Seoul : Samsung Medical Center

Clinical Trial of Donepezil Between the Naive Group and the Switching Group

Seoul : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Seoul : Pfizer Investigational Site

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Seoul : The Catholic University of Korea, Seoul St. Mary's Hospital

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Seoul : Kyung Hee University Oriental Medicine Hospital

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Seoul City : Samsung Medical Center

Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia

Suwon : The Catholic University of Korea, St. Vincent's Hospital

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Netherlands

Poland

Gdynia : Site Reference ID/Investigator# 62565

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Poznan : Site Reference ID/Investigator# 62563

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Szczecin : Site Reference ID/Investigator# 62562

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Romania

Arad : Spitalul Judetean de Urgenta Arad, Clinica de Psihiatrie

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Focsani : Spitalul de Urgenta "SF. Pantelimon" Focsani

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Iasi : Spitalul Clinic de Psihiatrie Socola Iasi

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Oradea : Crucea Alba - Dr. Oros si Asociatii - Societate Civila Medicala

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Sibiu : Spitalul Clinic Judetean de Urgenta SIBIU

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

View More »

Sibiu : Spitalul de Psihiatrie Sibiu

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Timisoara : Spitalul Clinic Judetean de Urgenta, Clinica Psihiatrie

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Timisoara : Spitalul Clinic Judetean de Urgenta, Clinica Neurologie 2

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Russian Federation

Kazan : Site Reference ID/Investigator# 60955

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Kazan : Site Reference ID/Investigator# 60945

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Kirov : Site Reference ID/Investigator# 60954

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Moscow : Site Reference ID/Investigator# 60959

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Moscow : Site Reference ID/Investigator# 60951

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

View More »

Novosibirsk : Site Reference ID/Investigator# 60946

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Saratov : Site Reference ID/Investigator# 60950

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

St. Petersburg : Site Reference ID/Investigator# 60952

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

St. Petersburg : Site Reference ID/Investigator# 60947

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

St. Petersburg : Site Reference ID/Investigator# 60949

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

St. Petersburg : Site Reference ID/Investigator# 60958

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Slovakia

Banska Bystrica : Neurologicka Ambulancia, s.r.o.

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Bratislava : Univerzitna nemocnica Bratislava, Geronto-psychiatrické oddelenie

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Dubnica nad Váhom : KONZILIUM s.r.o.

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Krompachy : Neurologická ambulancia

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

South Africa

Belville : Site Reference ID/Investigator# 60911

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Belville : Site Reference ID/Investigator# 67586

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Belville : Site Reference ID/Investigator# 73507

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Cape Town : Site Reference ID/Investigator# 67582

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

George : Site Reference ID/Investigator# 60912

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

View More »

George : Site Reference ID/Investigator# 67584

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Johannesburg : Site Reference ID/Investigator# 60910

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Johannesburg : Site Reference ID/Investigator# 67585

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Rosebank : Site Reference ID/Investigator# 67583

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Spain

Barcelona : Funcació ACE

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

Barcelona :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Barcelona :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Elche :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Granada : Clinical Nutrition and Dietetic Unit, University Hospital Virgen de las Nieves

Evaluation of a Diet in Patients With Senile Dementia

View More »

Granada : Department of Biochemistry and Molecular Biology II. University of Granada

Evaluation of a Diet in Patients With Senile Dementia

Madrid :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Sevilla :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Sweden

Stockholm : Investigational Site Number 752001

Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients

Ukraine

Dnipropetrovsk : Dnipropetrovsk Regional Clinical Hospital

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Donetsk : Donetsk Regional Clinical Psychiatric Hospital

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Donetsk : Site Reference ID/Investigator# 60909

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Kharkiv : Central Clinical Hospital Ukrzaliznytsi

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Kiev : Site Reference ID/Investigator# 60906

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

View More »

Kyiv : Department of Age Physiology and Pathology of Nervous System; Institute of Gerontology NAMS

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Lugansk : Lugansk Regional Clinical Psychoneurological Hospital

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Lviv : Lviv National Medical University named after Galytskyy

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Odessa : Odessa Regional Psychiatric Hospital # 2

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Odessa : Odessa Regional Psychoneurology Dispensary

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Poltava : Poltava Regional Clinical Psychiatric Hospital

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Poltava : Site Reference ID/Investigator# 60905

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Stepanovka : Department #3 of the Kherson Regional Psychiatric Hospital

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

United Kingdom

Bath : Site Reference ID/Investigator# 60960

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Bath : Site Reference ID/Investigator# 67787

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Blackburn : Site Reference ID/Investigator# 60963

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Blackburn : Site Reference ID/Investigator# 73503

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Bradford : MAC Clinical Research

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

View More »

Cambridge : GSK Investigational Site

Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects

Crowborough : Grove House

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

Glasgow : Site Reference ID/Investigator# 60962

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Glasgow : Site Reference ID/Investigator# 67784

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

London : Site Reference ID/Investigator# 60961

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

London : Site Reference ID/Investigator# 67786

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Manchester : Site Reference ID/Investigator# 67785

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Oxford : Warneford Hospital

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

Southampton : Memory Assessment and Research Centre, Moorgreen Hospital

Safety and Tolerability of Etanercept in Alzheimer's Disease

Staffordshire : MAC Clinical Research

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

Warrington : Site Reference ID/Investigator# 67783

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors